TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06346574

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: Participants will receive access to health and wellness app and guide

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Participants will receive access to health and wellness app and guide
Study: NCT05092672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min
Study: NCT01952886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study: NCT05617508

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered twice daily for a total of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside supplementation 1000mg daily in total
Description: Nicotinamide Riboside supplementation 1000mg daily in total

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)
Description: Nicotinamide Riboside supplementation up to 3000mg daily in total
Study: NCT05051579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05301517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEPO®
Description: SEPO® will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Study: NCT06420089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senza5 CART5
Description: The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senza5 CART5
Description: The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
Study: NCT05915299

Intervention type: DEVICE
Intervention: OCS Heart
Description: The TransMedics® Organ Care System (OCS) Heart System is an FDA approved portable extracorporeal heart perfusion and monitoring system.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation.
Study: NCT05245201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical decision support for PrEP
Description: Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
Study: NCT05349630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
Study: NCT05638425

Intervention type: RADIATION
Intervention: Radiotherapy combined with PD-1 inhibitors
Description: Radiotherapy should be carried out within 4 weeks after the first dose of PD-1 inhibitor; the radiotherapy method should be determined according to the patient's condition; PD-1 inhibitor and chemotherapy should refer to the actual product instructions
Study: NCT06693089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIT-ED
Description: The aim is to develop healthier strategies for managing negative thoughts and feelings linked to Eating Disorder (ED) and engage patients in social interactions that fulfill their relational needs. Participants will learn that perfectionism and the need for control in ED are coping strategies shaped by interpersonal patterns with significant others, where low self-esteem and emotional dysregulation play key roles. Metacognitive Intepersonal Therapy (MIT) aims to improve individuals' ability to understand their own emotions and thoughts, recognizing maladaptive, rigid, and biased schemas about self and others. This awareness helps them form a richer understanding of others' minds and use this knowledge to respond more adaptively to social challenges. MIT also helps individuals reflect on how these schemas trigger ED behaviors and develop better coping strategies for interpersonal stressors.
Study: NCT06727305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 0.5 Mg Oral Tablet
Description: Sirolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 1Mg Oral Tablet
Description: Sirolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 2 MG Oral Tablet
Description: Sirolimus 2 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus 0.5 MG Oral Tablet
Description: Everolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus 1 MG Oral Tablet
Description: Everolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus 2 MG Oral Tablet
Description: Everolimus 2 mg oral tablets for daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
Study: NCT05568732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedure will be done with VCMX
Description: Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage procedure will be done with CTG
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
Study: NCT05152758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARx
Description: Prescription Physical Activity Programming Application
Study: NCT06106620

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink consisting of 12 oz of flavor-matched water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Safety Shot
Description: Safety Shot consisting of a 12 oz drink containing vitamins, mineral, and botanical extracts.
Study: NCT05471830

Intervention type: DRUG
Intervention: Apixaban
Description: No drug will be provided to participants. Patients follow routine clinical practice/administration.
Study: NCT05385432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti thymocyte globulin (rATG)
Description: The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
Study: NCT06472492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjuvant yoga intervention
Description: The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.
Study: NCT05802589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Erector Spinae Plane Block
Description: Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group Block
Description: Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no peripheral block
Description: No peripheral block was applied. Standard multimodal analgesia method was applied.
Study: NCT05011812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 1
Description: Dose level 1 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 1
Description: Dose level 1 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 2
Description: Dose level 2 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 2
Description: Dose level 2 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 2
Description: Dose level 2 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 3
Description: Dose level 3 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 3
Description: Dose level 3 of PBI-0451
Study: NCT05385432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Simulect® IV 40mg D0 and D4
Study: NCT05011812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 4
Description: Dose level 4 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 4
Description: Dose level 4 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be co-administered with the study drug in Treatments J and K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be co-administered with the study drug in Treatments J and K
Study: NCT05903352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continue the antimicrobial treatment
Description: Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
Study: NCT05426785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1:1 ratio for Treatment Group and Control Group
Description: Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
Study: NCT05011812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be co-administered with the study drug in Treatment L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study: NCT05151185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management Service Program
Description: The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program: Needs Assessment, Intervention, evaluation and follow up, etc. The case management program is provided by a trained case manager in a dementia clinic, as well as telephone consultations and follow-up are provided.
Study: NCT05729321

Intervention type: COMBINATION_PRODUCT
Intervention: neutrox
Description: Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
Study: NCT05106907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19 cells
Description: 0.2-60 x 10\^6 CAR T cells per kg body weight
Study: NCT04763967

Intervention type: DEVICE
Intervention: PedSCath Pediatric Urinary Catheter
Description: PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.

Intervention type: DEVICE
Intervention: Standard of Care
Description: Current Standard of Care for pediatric patients
Study: NCT05129696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (T)
Description: Children area offered to participate in bimonthly group sessions. Each session will have materials and activities appropriate for children spanning a 6-month range (6-12 m, 12-18 m, 12-24 m, 24-30 m) and can accommodate a maximum of 10 children per age group. If more households are interested than can be accommodated by the program, interested families will be randomly selected for participation. A total of 40 children per site will be able to participate in the ECD activities at any one time. With bi-monthly meetings, each child will be exposed to 12 sessions for each age group, and is eligible to transition to the next.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment + (T+)
Description: Caregivers/children participating to the group ECD sessions will be invited to play within a play space equipped with books, and homemade/purchased age-appropriate toys. This will be phased in after 6 months of implementation.
Study: NCT05011812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451
Description: Dose level of PBI-0451 with a projected exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451
Description: Dose level of PBI-0451 with a projected exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451
Description: Dose level of PBI-0451 with a projected exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 5
Description: Dose level 5 of PBI-0451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 5
Description: Dose level 5 of PBI-0451
Study: NCT04804683

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic dissection of Fibromuscular Dysplasia
Description: Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia

Intervention type: OTHER
Group type: OTHER
Intervention: Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia
Description: Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
Study: NCT06106126

Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 100mg Tablets and ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 100mg Tablets and ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 100mg Tablets and ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 100mg Tablets and ritonavir
Study: NCT00687180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with mycophenolat mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with azathioprin
Study: NCT06007521

Intervention type: OTHER
Intervention: interview with neurologist
Description: interview with neurologist
Study: NCT04932109

Intervention type: OTHER
Intervention: No intervention
Description: No intervention in this group

Intervention type: OTHER
Intervention: No intervention
Description: No intervention in this group

Intervention type: OTHER
Intervention: No intervention
Description: No intervention in this group
Study: NCT04670211

Intervention type: DEVICE
Intervention: maxillary distractor
Description: the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor

Intervention type: DEVICE
Intervention: maxillary distractor
Description: the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor

Intervention type: DEVICE
Intervention: maxillary distractor
Description: the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
Study: NCT06102551

Intervention type: BEHAVIORAL
Intervention: Recurrence after surgery
Description: Recurrence after repair was the main outcome
Study: NCT05203315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duobrii 0.01 % / 0.045 % Topical Lotion
Description: Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duobrii 0.01 % / 0.045 % Topical Lotion
Description: Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraVe, Topical Cream
Description: CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraVe, Topical Cream
Description: CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
Study: NCT05181072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced in-person peer-motivation smoking cessation
Description: Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual peer-motivation smoking cessation
Description: This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
Study: NCT04796974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cention
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
Study: NCT04984239

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy for aphasia
Description: The intervention will consist of Acceptance and Commitment Therapy modified to meet the needs of stroke survivors with aphasia, combined with communication strategy training.
Study: NCT06027203

Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: Prostate biopsy by either transrectal or transperineal technique

Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: Prostate biopsy by either transrectal or transperineal technique